Skip to main content

Advertisement

SpringerLink
Log in

2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis

  • Liver, Pancreas, and Biliary Tract
  • Published:
Gastroenterologia Japonica Aims and scope Submit manuscript

Summary

The 2′-5′ oligoadenyIate synthetase (2-5 AS) activity of peripheral blood mononuclear cells and serum was measured in 23 patients with chronic non-A, non-B hepatitis during interferon therapy, 16 of whom were found to have antibody to hepatitis C virus (anti-HCV). Patients received a daily dose of either 1 million, 3 million or 6 million units of human interferon-αor-β for 4 to 6 weeks. Before treatment, the 2-5 AS activity was not significantly different from that in normal control subjects or patients with chronic hepatitis B. However, during treatment the 2-5 AS activity increased 2- to 41-fold from the initial level. AIanine aminotransferase (ALT) levels normalized promptly after the start of treatment in 15 (65.2%) of the 23 patients, but remained elevated in the remaining 8 (34.8%). Six (40%) of the 15 patients showed consistently normal ALT levels for 6 to 30 months after the end of treatment. There was no significant difference between the responders and non-responders in the pattern of change of 2-5 AS activity, but pretreatment activity levels in peripheral blood mononuclear cells were significantly higher (P< 0.001) in the patients whose ALT levels did not normalize during treatment. The frequency of patients with a positive anti-HCV was significantly higher (P< 0.05) in the group in which ALT levels normalized. Therefore, these findings suggest that the pretreatment 2-5 AS activity and the detection of anti-HCV may be useful parameters for predicting the response to interferon therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Choo Q-L, Kuo G, Weiner AJ, et al: IsoIation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–362.

    Article  PubMed  CAS  Google Scholar 

  2. Kuo G, Choo Q-L, Alter RJ, et al: An assay for circuIating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362–364.

    Article  PubMed  CAS  Google Scholar 

  3. Koretz RL, Stone O, Moussa M, et al: Non-A, non-B posttransfusion hepatitis-a decade Iater. Gastroenterology 1985;88: 1251–1254.

    PubMed  CAS  Google Scholar 

  4. Realdi G, Albenti A, Rugg M, et al: Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982;23:270–275.

    Article  PubMed  CAS  Google Scholar 

  5. Hoofnagle JH, Mullen KD, Jones DB, et al: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha intcrferon: a preliminary report. N Engl J Med 1986:315:1575–1578.

    Article  PubMed  CAS  Google Scholar 

  6. Thomson BJ, Doran M, Lever AML, et al: Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin repIacement therapy. Iancet 1987;I:539–541.

    Google Scholar 

  7. Davis GL, Balart Ia, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501–1506.

    Article  PubMed  CAS  Google Scholar 

  8. Di Bisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, pIacebo-controlled trial. N Engl J Med 1989;321: 1506–1510.

    Article  PubMed  Google Scholar 

  9. Kerr IM, Brown RE. ppA2′p5′A2′p5′A: an inhibition of protein synthesis synthesized with an enzyme fraction from interferontrcated cells. Proc Natl Acad Sci USA 1978;75:256–260.

    Article  PubMed  CAS  Google Scholar 

  10. Beglioni C. Interferon induced enzymatic activities and their role in the antiviral state. Cell 1979;17:255–264.

    Article  Google Scholar 

  11. Schattner A, WalIach D, Merlin G, et al: Assay of an interferonindued enzyme in white blood cells as a diagnostic aid in viral diseases. Iancet 1981;II:497–499.

    Google Scholar 

  12. Sugino H, Mitani I, Koike M, et al: Detection of elevated levels of 2-5A synthetase in serum from children with various infectious diseases. J Clin Microbiol 1986:24:626–628.

    Google Scholar 

  13. Poitrine A, Chousterman S, Chousterman M, et al: Iack ofin vivo activation of the interferon system in HBs Ag-positive chronic active hepatitis. Hepatology 1985;5:171–174.

    Article  PubMed  CAS  Google Scholar 

  14. Peters M, Davis GL, Dooley JS, et al: The interferon system in acute and chronic viral hepatitis. In: Popper H, Schaffner F, eds. Progress in liver diseases. Vol 8, Grune & Stratton, New York 1986;453–467.

    Google Scholar 

  15. Shindo M, Okuno T, Matsumoto M, et al: Serum 2′,5′oligoadenyIate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 1988;8:366–370.

    Article  PubMed  CAS  Google Scholar 

  16. International group: Acute and chronic hepatitis revisited. Iancet 1977;II:914–919.

    Google Scholar 

  17. Shindo M, Okuno T, Arai K, et al: Elevated levels of 2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B. Hepatology 1989;9:715–719.

    Article  PubMed  CAS  Google Scholar 

  18. Peters M, Walling DM, Kelly K, et al: Immunologie effects of interferon-α in man: treatment with human recombinant interferon-α suppressesin vivo immunoglobulin production in patients with chronic type B hepatitis. J Immunol 1986:137:3147–3152.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Akashi Municipal Hospital, 1-33 Takashomachi, Akashi, 673, Hyogo, Japan

    Tadao Okuno M.D.

  2. Third Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Michiko Shindo, Ken Arai & Kei Kashima

  3. Department of Internal Medicine, SaiScikai Kyoto Hospital, Kyoto, Japan

    Masayuki Matsumoto

  4. Department of Internal Medicine, Rakuwakai Marutamachi Hospital, Kyoto, Japan

    Makoto Takeda

  5. Department of Biotechnology, Kyoto Institute of Technology Kyoto, Japan

    Yoshihiro Sokawa

Authors
  1. Tadao Okuno M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michiko Shindo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayuki Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kei Kashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihiro Sokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okuno, T., Shindo, M., Arai, K. et al. 2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis. Gastroenterol Jpn 26, 603–610 (1991). https://doi.org/10.1007/BF02781676

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02781676

Key words

Search

Navigation